CN105963327A - Vitamin K2 composition for prevention and treatment of liver function impairment - Google Patents
Vitamin K2 composition for prevention and treatment of liver function impairment Download PDFInfo
- Publication number
- CN105963327A CN105963327A CN201610298501.1A CN201610298501A CN105963327A CN 105963327 A CN105963327 A CN 105963327A CN 201610298501 A CN201610298501 A CN 201610298501A CN 105963327 A CN105963327 A CN 105963327A
- Authority
- CN
- China
- Prior art keywords
- liver
- compositions
- menaquinone
- composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Insects & Arthropods (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Animal Husbandry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a composition containing vitamin K2 as well as applications thereof to prevention and treatment of diseases with liver function impairment. The composition comprises the following components with efficacies in percentages by weight: 0.0001-12% of vitamin K2, 0.0001-10% of nutritional selenium, 10-60% of taurine, 5-50% of royal jelly, and balance being an auxiliary material. Components with efficacies are scientifically compatible, and components have mutually synergistic effects, so that the composition has substantial efficacies for reducing liver injury, promoting regeneration of hepatocyte, and recovering liver functions; the composition is used for preventing and treating common hepatitis, alcoholic liver, fatty liver, chemical liver injury, liver cirrhosis, and liver cancer.
Description
Technical field
The invention belongs to functional preparation formula technique field, be specifically related to a kind of containing Menaquinone K6 functional component, have
The liver protecting, prevents and treats the compositions of liver dysfunction.
Background technology
Liver is organ maximum in human body viscera, is also toxin expelling place important in human body, to ex vivo with external
Many non-nutritive substances and some metabolite internal there is biotransformation.With advancing age, liver merit
Can will be decreased obviously due to hepatic blood flow and the minimizing of hepatocyte quantity: it's 25 years old pasts male, after it's 20 years old pasts women, liver
Blood flow declines 0.3%～1.5% every year on average, in liver when 60 years old blood flow about than 20 years old time reduce 40%～
50%；Hepatocyte quantity increases with the age and falls sharply, and liver tends to cirrhosis, and weight is decreased obviously, putting down of 90 years old old people's liver
All weight only has the 51.8% of about 30 years old adolescence's liver weight.Meanwhile, along with the increasing the weight of of environmental pollution, the mistake of fuel value of food
The impact of the factors such as degree picked-up and bad life habits, liver function damage has become the disease that city " subhealth state " crowd is common
Shape, causes the occurred frequently of various hepatitis, alcoholic liver and the hepatic disease such as fatty liver, some also can be further developed into into liver cirrhosis,
Hepatocarcinoma.After hepatocyte once canceration, there is the highest fatality rate and relapse rate, even early hepatocarcinoma patient is through radical-ability hands
Postoperative relapse rate is still up to 80%, has the liver cancer patient of 50%～90% to die from cancer return.Therefore, develop and a there is guarantor
Liver-protecting function, it is possible to the functional preparation tool reducing liver canceration and liver cancer recurrence risk is of great significance.
Menaquinone K6 is the compound that a class is referred to as methylnaphthoquinone (MK), containing 2-MNQ parent nucleus and C3
Bit strip has the isopentene group construction unit that quantity does not waits, and its chemical structural formula is shown below.Naturally occurring Menaquinone K6 divides
In son, the span of isopentene group construction unit n is 1-13, can be synthesized by some intestinal bacteria in human body.Menaquinone K6
Having good safety, current result of study shows its without any side effects and untoward reaction to human body.
Menaquinone K6 can suppress the growth of human liver cancer cell, and the apoptosis of induction human liver cancer cell, preventing viral liver is hard
Change and hepatitis C liver cirrhosis progress to the research existing pertinent literature report of hepatocarcinoma, but up to now, have no have prevention and treatment
The Related product of the Menaquinone K6 compositions of liver dysfunction.
Summary of the invention
It is an object of the invention to provide a kind of containing Menaquinone K6 functional component, there is prevention and treatment liver dysfunction
Compositions.
Of the present invention a kind of prevention and treatment liver dysfunction Menaquinone K6 compositions, it is characterised in that it by
The component composition of following weight percents:
The preferred ingredient percentage by weight of the present invention is:
In said components, Menaquinone K6 refers to menadione-2 (MK-of isoprenoid group pendant length on naphthoquinone framework
2) to the homologue of menadione-13 (MK-13), it is preferred that select there is the MK-4 (MK-4) of higher physiologically active to first
Naphthoquinone-9 (MK-9), the menaquinone-7 (MK-7) of particularly preferred Gamma Magnitude consumption is to menadione-9 (MK-9).When selecting MK-7 extremely
During MK-9, in compositions, the human body daily intaking amount of Menaquinone K6 only needs 25-1000 microgram.Menaquinone K6 in the present invention can be from appointing
What suitable source obtains, the method such as including natural product extraction, fermentable and chemosynthesis.Dimension in the present invention is raw
Element K2 can use highly purified Menaquinone K6, it is possible to use with edible vegetable oil, starch, calcium hydrogen phosphate, beta-schardinger dextrin-, crystallite fibre
Dimension element waits the Menaquinone K6 commercially produced product of the various content specifications for substrate preparation.
In said components, nutrition selenium refers to used in drug additive, food additive and health food nutrient
Selenocarrageenan, yeast rich in selenium, selenocysteine, sodium selenate, sodium selenite or selenomethionine.
In said components, taurine refers to taurine or the taurine of synthetic extracted from biology.
In said components, Lac regis apis refers to Lac regis apis lyophilized powder or honey with royal jelly.
In said components, adjuvant refers in starch, calcium hydrogen phosphate, beta-schardinger dextrin-, microcrystalline Cellulose, vegetable oil, Cera Flava
One or more.
The present invention can be prepared by methods well known in the art becomes any oral liquid or solid preparation.Dimension is raw
Element K2 belongs to fatsoluble vitamin, and preferred dosage form is capsule or tablet.
Said vitamin K2 compositions, it is characterised in that said composition is treated at protection and the liver damage disease of liver function
The application of aspect, can be used for prevention and the treatment of hepatitis, alcoholic liver, fatty liver, chemical liver injury, liver cirrhosis and hepatocarcinoma.
Below in conjunction with the main active of the present invention, further illustrate effect of the present invention.
One important feature of the present invention is Menaquinone K6 to the prevention of the liver damage disease including hepatocarcinoma and auxiliary
Therapeutical effect.A series of research report is had to indicate the Menaquinone K6 effect at antagonism liver cancer: Menaquinone K6 is at constitutional
Content in liver cancer tissue is significantly lower than Tumor-surrounding tissue；Abnormal prothrombin be a kind of because of vitamin K deficiency or by antagonism time produce
Raw material, is applied to clinic by the tumor markers as diagnosing primary hepatocarcinoma；Liver cirrhosis patient gives vitamin
After K2 treatment, the incidence rate of hepatocarcinoma is significantly lower than matched group；Menaquinone K6 can alleviate rat 2/3 hepatectomy and drug toxicity to liver
The infringement of dirty cell, accelerates postoperative transaminase level and declines and strengthen Hepatocyte synthesis capability；Patients with Primary is entered
The relapse rate that the treatment of row radical excision postoperative auxiliary Menaquinone K6 can reduce after operation in patients in 3 years, corresponding to improve its accumulation raw
Deposit rate.
Another important feature of the present invention is the acceleration repair to hepatic injury of the nutrition selenium.Selenium is required in human organism
Trace element, has different physiological roles, and its prominent effect is antioxidation, is in the activity of glutathion peroxidase
The heart.Drug induced hepatitis and alcoholic liver are as a kind of liver-injuring disease, and one of its pathology is exactly the glutathion consumption in hepatocyte
Exhaust.This " exhaustion " is that liver includes the glutathion peroxidase of selenium and is persistently catalyzed and utilizes glutathion, to eliminate excess
The result of free radical, is the consequence of liver " fatigue ".Therefore, suitable Selenium Supplement element is to improve internal glutathion peroxide
Compound enzyme level, alleviates liver inner lipid extent of peroxidation, liver lesion induced by drugs injures alcoholic liver and can play what acceleration was repaired
Effect.
The present invention also has an important feature to be the taurine protective effect to hepatic tissue.Liver is the target that taurine is important
Organ, in the animal model that taurine lacks, it can be observed that the abnormal development of liver organization or incomplete phenomenon.With
Time, multiple hepatic disease can be played good therapeutic effect by antioxidation by taurine to have substantial amounts of research to show,
Jaundice that such as acute hepatitis causes, hepatic encephalopathy, liver cirrhosis patient muscle spasm etc. it can also be used to resist multiple liver
Toxin, such as carbon tetrachloride, acetaminophen, ethanol, thioacetamide etc..Hepatic cell fattydegeneration number after taurine intervention
Amount significantly reduces, and fat vacuole denaturation degrees substantially alleviates.
The present invention is also added into Lac regis apis as functional component.Modern nutriology and medical research show, contain in Lac regis apis
There is abundant aminoacid, saccharide, vitamin and trace element, liver is had good maintenance action: arginine can help liver
Dirty dispel toxin；Saccharide can be hepatopath's additional heat；Vitamin A, C, E participate in multiple metabolism in liver, strengthen liver detoxification
Function；The trace element such as ferrum, copper, zinc, cobalt, manganese play an important role in the enzymes metabolism of liver.
Instant invention overcomes and prior art exists the deficiency that composition is single and effect is not good enough, by effect each in compositions
The scientific compatibility of composition and mutual Synergistic, reach to reduce hepatic injury, promote liver regeneration, the purpose of recovery liver function.
(1) main, the sensitivity index of hepatic injury is controlled.Transaminase is that reflection hepar damnification is the most most sensitive
Index, the recovery to liver regeneration and liver function is significant.Aspartate amino transferase change reflection hepatocyte line
Plastochondria degree of injury.Serum alanine aminotransferase change reflection liver plasma membrane degree of injury.Albuminous change reflection liver
Cell synthetic proteins ability, albumin reduces degree parallels with liver damage degree.Research shows, Menaquinone K6 can significantly change
Kind These parameters, reduces hepatic injury, promotes the recovery of liver regeneration and liver function.
(2) each component is respectively arranged with function and stresses, Synergistic the most again.Menaquinone K6 is responsible for entering main hepatic injury index
Row regulation and control, especially with promote wounded hepatocytes be regenerated as emphasis；Abundant aminoacid that Lac regis apis contains, saccharide, vitamin and
Trace element, has nutrition liver, increases Liver immunity power and promote the important function of liver detoxification；Utilize the notable antioxygen of selenium
Change effect, accelerate to repair hepatic injury cell；Taurine then by anti-lipid peroxidation, improve Defensive Enzyme, resist multiple
Hepatotoxin and antagonism film decomposing protection hepatocyte.This compositions is started with from multiple links, by mutual Synergistic, real
Show the treating both the principal and secondary aspects of a disease of the treatment to wounded hepatocytes, functional rehabilitation and maintenance.
(3) composition effect is notable.Research shows, when liver sustains damage and suffers from various hepatopathy, and internal reproducibility paddy
The sweet peptide of Guang (GSH) will fall sharply, and when hepatopathy virus increases and replication capacity strengthens, the triglyceride (TG) of liver will be inclined
High.Test shows, this compositions can significantly raise reductive glutathione and reduce content of triglyceride in liver organization, helps
Impaired liver self-regeneration, to viral hepatitis (such as hepatitis A, hepatitis B etc.), alcoholic liver disease, drug-induced liver disease, fatty liver etc.
Liver damage disease has significantly prevention and therapeutic effect.
Detailed description of the invention
It is further elucidated with the present invention below in conjunction with specific embodiment.It is pointed out that embodiment is merely to illustrate this
Bright rather than limit the scope of the present invention, nonessential amendment that other people make and adjustment according to the prompting of the present invention, still
Belong to protection scope of the present invention.The experimental technique of unreceipted actual conditions in the following example, generally according to normal condition, or
According to the condition proposed by manufacturer.Unless stated otherwise, following ratio and percentage ratio are based on weight.
The preparation of composition soft agent described in embodiment 1
Utilize routine techniques, uniformly mix following components, then prepare glue with gelatin, glycerol, pure water for primary raw material
Liquid, carries out pelleting by component and glue on encapsulating machine.The proportioning of its component is as follows:
The preparation of composition tablet described in embodiment 2
Utilizing routine techniques, uniformly mix following components, be then pressed into tablet, its proportioning is as follows:
Animal contractile studies
1. test basis: use the soft capsule that above-described embodiment 1 is made, according to Ministry of Public Health " health food inspection and evaluation
Technical specification " regulation of (2003 editions) carries out animal function test and evaluation of test result.
2. laboratory animal and rearing conditions
Experiment ICR kind mice is provided by the clear new drug research centered finite company of spreading out in Suzhou, body weight 15～17g when buying.
Laboratory animal feedstuff is worked in coordination with medical bioengineering company limited by Jiangsu and is provided, and " experiment is dynamic to perform standard GB14924.3-2010
Thing mixed feed nutritional labeling ".Drinking water is sterilizing urban drinking water, meets National Standard of the People's Republic of China's " life drink
Use water hygiene standard " regulation of (GB5749-2006).Feeding environment: temperature range 22～24 DEG C, RH range 40～
70%.Adapt to 4 days in Animal House environment before laboratory animal experiment.
3. dose design
This experiment sets basic, normal, high three groups of dosage groups, and dosage is as follows:
Low dose group 83.5mg/kg bw, is equivalent to 5 times of people's recommended daily dosage；
Middle dosage group 167mg/kg bw, is equivalent to 10 times of people's recommended daily dosage；
High dose group 500mg/kg bw, is equivalent to 30 times of people's recommended daily dosage.
4. data process
Experimental data is with mean+SDRepresenting, variance analysis and statistical test use Sun Ruiyuan
Deng: many groups mean analysis in DAS statistical software, first data are carried out homogeneity test of variance, if variance is neat, uses single factor test variance
Analysis is totally compared, find differences again with T method of inspection carry out between multiple dosage group and a matched group mean two-by-two than
Relatively, if heterogeneity of variance, use rank test instead and add up.
5. experiment content
5.1 on Mouse Weight impact test
5.1.1 experimental technique
Taking 75 experiment mices, be randomly divided into 5 groups by body weight, often group 15, gavage is to sample liquid and vegetable oil (gold respectively
Dragon milt refining one-level soybean oil, as follows), once a day, continuous 32 days.Before for the first time giving sample (starting weight), to sample the
15 days (middle weight), to sample the 32nd day (weight eventually), use TD10021 type electronic balance and TD2102 type electronic balance to weigh mice
Body weight.
5.1.2 experimental result
The results are shown in Table 1.Initial data all meets homogeneity of variance requirement, compares with blank group, model group, three grades two groups
The Mouse Weight difference at experiment initial stage, mid-term and final period there are no significant meaning (P ＞ 0.05).
The table 1 impact on Mouse Weight
In 5.2 pairs of alcoholic hepatic injury model mice liver organizations, reductive glutathione (GSH) and triglyceride (TG) contain
It is fixed to measure
5.2.1 experimental technique
Taking experiment mice 50, body weight 18～22g, be randomly divided into 5 groups, gavage is to sample liquid and vegetable oil respectively, often
It once, continuous 36 days.After last gavage, model group and 3 disposable gavages of dose sample group give 50% ethanol 12ml/kg
Bw, blank group gives distilled water, and after fasting 16 hours, dislocation method puts to death mice, after taking liver homogenate, uses Nanjing to build up
Reductive glutathione (GSH), triglyceride (TG) that Bioengineering Research Institute provides measure test kit and measure liver organization
Middle reductive glutathione (GSH) and triglyceride (TG) content, concrete detection process is all carried out according to test kit operation requirement.
5.2.2 experimental result
5.2.2.1 reductive glutathione (GSH) assay result
The results are shown in Table 2, initial data meets homogeneity of variance requirement.Compare with blank group, model control group liver group
Knitting middle GSH content to reduce, difference has significant (P ＜ 0.01), illustrates that alcoholic hepatic injury model is set up.With model control group
Relatively, middle and high dosage group GSH content all raises, and difference all has significant (P ＜ 0.05).
Table 2 is on the impact of reductive glutathione content in mouse liver tissue
Note: compare with blank group,△△P ＜ 0.01；Compare with model control group,*P ＜ 0.05；**P ＜ 0.01
5.2.2.2 triglyceride (TG) assay result
The results are shown in Table 3, initial data meets homogeneity of variance requirement.Compare with blank group, model control group liver group
Knitting middle TG content to raise, difference has significant (P ＜ 0.01), illustrates that alcoholic hepatic injury model is set up.With model control group
Relatively, basic, normal, high dosage group TG content all reduces, and difference all has significant (P ＜ 0.01).Illustrate that this health food can
To reduce content of triglyceride in liver organization.
Table 3 is on the impact of content of triglyceride in mouse liver tissue
Note: compare with blank group,△△P ＜ 0.01；Compare with model control group,**P ＜ 0.01
5.3 alcoholic hepatic injury model mice histopathology detections
5.3.1 experimental technique
Taking experiment mice 50, body weight 18～22g, be randomly divided into 5 groups, gavage is to sample liquid and vegetable oil respectively, often
It once, continuous 36 days.After last gavage, model group and 3 disposable gavages of dose sample group give 50% ethanol 12ml/kg
Bw, blank group gives distilled water, and after fasting 16 hours, dislocation method puts to death mice, takes liver left middle lobe portion and does cross section and take
Material, frozen section, oil red dyes.Microscopy starts to record the pathological change of cell from the visual field, one end of liver, with 40 times of object lens
The whole tissue slice of Continuous Observation, main detection fat drops in the distribution of liver, scope and area.Give a mark by table 4.
Table 4 alcoholic hepatic injury model mice histopathology detection standards of grading
5.3.2 experimental result
The results are shown in Table 5, initial data meets homogeneity of variance requirement.Compare with blank group, model control group Mouse Liver
Dirty cellular fat degeneration score value is significantly raised, and difference has significant (P ＜ 0.01), illustrates that alcoholic hepatic injury model becomes
Vertical.Comparing with model control group, basic, normal, high dosage group mouse liver cellular fat degeneration score average all reduces, and difference all has
Significant (P ＜ 0.01).
Table 5 mouse liver histopathology tissue change affects
Note: compare with blank group,△△P ＜ 0.01；Compare with model control group,**P ＜ 0.01
6. evaluation of result
Test result indicate that: this compositions is the positive, liver to glutathion (GSH), triglyceride (TG) index result
Histopathologic examination's result is also positive.According in " health food inspection and assessment technique specification ", chemical liver injury is had
Assistant protection function evaluation criterion judges, compositions of the present invention has prevention and the merit of auxiliary therapeutical chemistry hepatic injury
Energy.
Claims (12)
1. a prevention and the Menaquinone K6 compositions for the treatment of liver dysfunction, it is characterised in that include following percentage by weight
Composition:
The percentage by weight sum of each component is 100%.
Compositions the most according to claim 1, it is characterised in that preferred each weight percentages of components is:
The percentage by weight sum of each component is 100%.
Compositions the most according to claim 1 and 2, it is characterised in that described Menaquinone K6 can be from any suitable coming
Source obtains, the method such as including natural product extraction, fermentable and chemosynthesis；Highly purified Menaquinone K6 can be used,
It is used as the various content with edible vegetable oil, starch, calcium hydrogen phosphate, beta-schardinger dextrin-, microcrystalline Cellulose etc. as substrate preparation
The Menaquinone K6 commercially produced product of specification.
Compositions the most according to claim 3, it is characterised in that described Menaquinone K6 is from menadione-2 (MK-2) extremely
One or more in menadione-13 (MK-13) homologue.
Compositions the most according to claim 4, it is characterised in that the preferred MK-4 of described Menaquinone K6 (MK-4) is extremely
One or more in menadione-9 (MK-9), one in particularly preferred menaquinone-7 (MK-7) to menadione-9 (MK-9) or
Multiple.
Compositions the most according to claim 1 and 2, it is characterised in that described nutrition selenium refers at drug additive, food
Selenocarrageenan used in product additive and health food nutrient, yeast rich in selenium, selenocysteine, sodium selenate, sub-selenium
Acid sodium or selenomethionine.
Compositions the most according to claim 1 and 2, it is characterised in that described taurine refers to extraction from biology
Taurine or the taurine of synthetic.
Compositions the most according to claim 1 and 2, it is characterised in that described Lac regis apis refer to Lac regis apis lyophilized powder or
Person's honey with royal jelly.
Compositions the most according to claim 1 and 2, it is characterised in that described adjuvant refer to starch, calcium hydrogen phosphate, β-
One or more in cyclodextrin, microcrystalline Cellulose, vegetable oil, Cera Flava.
Compositions the most according to claim 1 and 2, it is characterised in that said composition can be made into any peroral dosage form.
11. composite preparations according to claim 10, it is characterised in that preferred dosage form is tablet or capsule.
12. compositionss according to claim 1 and 2, it is characterised in that said composition is in the protection of liver function and hepatic injury
Application in terms of disease treatment, can be used for hepatitis, alcoholic liver, fatty liver, chemical liver injury, liver cirrhosis and hepatocarcinoma prevention and
Treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610298501.1A CN105963327A (en) | 2016-05-05 | 2016-05-05 | Vitamin K2 composition for prevention and treatment of liver function impairment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610298501.1A CN105963327A (en) | 2016-05-05 | 2016-05-05 | Vitamin K2 composition for prevention and treatment of liver function impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105963327A true CN105963327A (en) | 2016-09-28 |
Family
ID=56992768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610298501.1A Pending CN105963327A (en) | 2016-05-05 | 2016-05-05 | Vitamin K2 composition for prevention and treatment of liver function impairment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105963327A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106889615A (en) * | 2017-02-06 | 2017-06-27 | 江南大学 | A kind of trace elements of selenium dietary supplements and its application with regulating intestinal canal flora function |
| WO2021000246A1 (en) * | 2019-07-02 | 2021-01-07 | 广东双骏生物科技有限公司 | Bacillus subtilis natto and method for producing protein mk-7 |
| CN117343134A (en) * | 2023-09-26 | 2024-01-05 | 大连深蓝肽科技研发有限公司 | Royal jelly peptide and cellulose carrier compound, preparation method and application thereof in treating liver injury diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101559216A (en) * | 2009-05-08 | 2009-10-21 | 刘进辉 | Amino acid composition capable of protecting kidney and liver as well as promoting growth for animal and preparation technique thereof |
| CN104688760A (en) * | 2015-02-02 | 2015-06-10 | 山东省中医药研究院 | Pharmaceutical composition composed of saikoside A and taurine and use thereof |
-
2016
- 2016-05-05 CN CN201610298501.1A patent/CN105963327A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101559216A (en) * | 2009-05-08 | 2009-10-21 | 刘进辉 | Amino acid composition capable of protecting kidney and liver as well as promoting growth for animal and preparation technique thereof |
| CN104688760A (en) * | 2015-02-02 | 2015-06-10 | 山东省中医药研究院 | Pharmaceutical composition composed of saikoside A and taurine and use thereof |
Non-Patent Citations (4)
| Title |
|---|
| 何昕: "《蜜蜂养殖与利用》", 30 April 2013, 中原农民出版社 * |
| 刘国华: "维生素K2对大鼠肝切除术后肝再生及肝功能恢复的影响", 《万方数据库》 * |
| 赵光等: "复方虫草片对小鼠抗体力性疲劳影响的实验研究", 《山东中医杂志》 * |
| 金香子等: "平肝解酒灵胶囊对小鼠酒精性肝损伤影响的实验研究", 《四川中医》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106889615A (en) * | 2017-02-06 | 2017-06-27 | 江南大学 | A kind of trace elements of selenium dietary supplements and its application with regulating intestinal canal flora function |
| CN106889615B (en) * | 2017-02-06 | 2021-03-30 | 江南大学 | Microelement selenium dietary supplement with function of regulating intestinal flora and application thereof |
| WO2021000246A1 (en) * | 2019-07-02 | 2021-01-07 | 广东双骏生物科技有限公司 | Bacillus subtilis natto and method for producing protein mk-7 |
| CN117343134A (en) * | 2023-09-26 | 2024-01-05 | 大连深蓝肽科技研发有限公司 | Royal jelly peptide and cellulose carrier compound, preparation method and application thereof in treating liver injury diseases |
| CN117343134B (en) * | 2023-09-26 | 2024-07-16 | 大连深蓝肽科技研发有限公司 | Royal jelly peptide and cellulose carrier compound, preparation method and application thereof in treating liver injury diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abdelnour et al. | Mitigating negative impacts of heat stress in growing rabbits via dietary prodigiosin supplementation | |
| AU2017320520B2 (en) | Use of collagen hydrolysate for improving endurance performance and for stimulating lipocatabolism | |
| Abdel-Aziem et al. | Evaluation of the alleviative role of Chlorella vulgaris and Spirulina platensis extract against ovarian dysfunctions induced by monosodium glutamate in mice | |
| CN101239069A (en) | Application of compound capable of supplying active methyl or engaging in methyl migration | |
| CN112206237A (en) | Anti-aging composition containing zinc taurate, preparation method and application thereof | |
| CN102215850A (en) | A composition comprising extraction of fucoxanthin | |
| WO2023005265A1 (en) | Application of nucleotide mixture in preparation of formulations for preventing or alleviating senile sarcopaenia | |
| US12023369B2 (en) | Use of collagen hydrolysate for improving endurance performance and for stimulating lipid catabolism | |
| JP2009249315A (en) | Mineral absorption promoter, and iron deficiency anemia-ameliorating agent or food composition | |
| CN105963327A (en) | Vitamin K2 composition for prevention and treatment of liver function impairment | |
| US8945532B2 (en) | Anti-aging formulations | |
| CN106722934A (en) | A kind of anti-ageing health food for containing peptide extract containing earthworm, clam worm | |
| JP2017031171A (en) | Pharmaceutical composition for preventing and treating liver fibrosis or nonalcoholic fatty liver disease | |
| Azad et al. | Effects of dietary carboxymethyl pachyman on oxidative stress and inflammation in weaned piglets challenged with diquat | |
| Ko et al. | Compound Cordyceps TCM-700C exhibits potent hepatoprotective capability in animal model | |
| CN111789078B (en) | Method for establishing rat non-obese non-alcoholic fatty liver disease model | |
| CN108514114A (en) | Composition for relieving physical fatigue and purposes based on chondriosome nutrient theory | |
| Shen et al. | Effect of echinacea purpurea extract given in drinking water on performance, slaughter variables, and meat quality of broilers | |
| Yeghaneh | Hypolipidemic effects of aqueous extract of onion (Allium cepa. Linn) on serum levels of cholesterol, triglycerides, LDL and HDL compared with Zn sulfate supplementation in the rats | |
| Cho et al. | Single-and repeated-dose toxicities of aloe fermentation products in rats | |
| CN113615833A (en) | Mitochondrial nutrient composition for improving cardiovascular disease and application thereof | |
| CN101716336A (en) | Yikang capsule and production process thereof | |
| CN110420270A (en) | A kind of functional composition containing camellia oil and fish oil and its application | |
| CN109364202A (en) | A kind of composition and its preparation method and application | |
| CN102793740B (en) | Nutrient particles with auxiliary protecting function on chemical liver injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160928 |